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Rapid Urine LAM Testing Improves 
Diagnosis of Expectorated Smear-
Negative Pulmonary Tuberculosis in 
an HIV-endemic Region
Paul K. Drain1,2, Lilishia Gounder3, Faieza Sahid4 & Mahomed-Yunus S. Moosa5
We sought to determine if urine lipoarabinomannan (LAM) would improve diagnosis of pulmonary 
TB. We enrolled consecutive adults presenting with ≥2 TB-related symptoms, obtained one induced 
sputum sample for smear microscopy (AFB) and mycobacterial culture, and performed urine LAM 
testing (DetermineTM TB LAM, Alere). We used culture-confirmed pulmonary TB as the gold standard, 
and compared accuracy with area under receiver operating characteristic curves (AUROC). Among 90 
participants, 82 of 88 tested (93%) were HIV-infected with a median CD4 168/mm3 (IQR 89–256/mm3).  
Diagnostic sensitivities of urine LAM and sputum AFB were 42.1% (95% CI 29.1–55.9%) and 21.1% 
(95% CI 11.4–33.9%), and increased to 52.6% (95% CI 39.0–66.0%) when combined. Sensitivity of 
LAM increased significantly among participants with a lower Karnofsky Performance score, anemia, 
hypoalbuminemia, and higher C-reactive protein. Combining LAM with AFB had an AUROC = 0.68 (95% 
CI 0.59–0.77), significantly better than AFB alone (AUROC=0.58; 95% CI 0.51–0.64). The combination 
of LAM and AFB was significantly better than AFB alone among patients with Karnofsky Performance 
score ≤90, hemoglobin ≤10 g/dL, albumin ≤25 g/L, C-reactive protein ≥25 mg/L, or CD4 <200/mm3.  
Urine LAM testing may be most beneficial among patients with functional impairment, elevated 
inflammatory markers, or greater immunosuppression.
Over 9 million people develop active tuberculosis (TB) disease each year, and TB is responsible for more deaths 
each year than any other infectious disease1. In addition, approximately one-third of cases are either not diag-
nosed or not recorded by national TB programs1,2. Performance of existing tests for diagnosing active TB have 
been suboptimal in HIV-endemic regions3,4. Sputum smear microscopy for acid-fast bacilli (AFB) has poor diag-
nostic sensitivity5–7, and mycobacterial sputum culture has limited availability in resource-limited settings8,9. The 
Xpert MTB/RIF assay has improved the diagnosis of active pulmonary TB, but the assay’s cost and reliance on 
electricity make the test less practical for use at the clinical point-of-care10,11. Thus, developing better diagnostic 
algorithms that utilizes existing, conventional tests or novel point-of-care assays for improved detection of pul-
monary TB remains a global public health priority1,2.
Lipoarabinomannan (LAM) is a lipopolysaccharide in the cell wall of M. tuberculosis that is released from 
organisms and excreted in urine12. A laboratory-based urine LAM-ELISA test had good diagnostic specificity, 
but poor sensitivity for diagnosing active TB disease13–15. A rapid, disposable lateral flow urine LAM assay can be 
conducted at the clinical point-of-care in 25 minutes16 and be used as a biomarker to predict mortality outcomes 
during anti-TB therapy17,18. Several studies, including our own, have demonstrated that the rapid urine LAM 
assay has adequate diagnostic specificity, but poor sensitivity16,19–24, which severely limits its utility as a solitary 
diagnostic test.
1Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA. 
2Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3Department 
of Virology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 
4Division of Infectious Diseases, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, 
University of the Witwatersrand, Johannesburg, South Africa. 5Department of Infectious Diseases, Nelson R. 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Correspondence and requests for 
materials should be addressed to P.K.D. (email: pkdrain@uw.edu)
Received: 02 September 2015
Accepted: 21 December 2015
Published: 11 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:19992 | DOI: 10.1038/srep19992
Since point-of-care diagnostics have many appealing properties for use in resource-limited settings25, we 
sought to determine if rapid urine LAM and induced sputum smear microscopy could improve diagnostic accu-
racy among adults with presumed sputum smear-negative pulmonary TB. Furthermore, since many point-of-care 
diagnostic tests, including C-reactive protein (CRP), hemoglobin, and CD4 count, have now emerged25, we addi-
tionally wanted to assess whether a combination of clinical, inflammatory, and immunologic markers would 
improve the diagnostic value of rapid urine LAM testing.
Methods
Study design and participant selection. We conducted a prospective cohort study of adults who were 
smear-negative by expectorated sputum, but presumed to have pulmonary TB on the basis of symptoms, at King 
Edward VIII Hospital in Durban, South Africa from November 2008 to December 200917. We enrolled con-
secutive participants ≥ 18-years-old with AFB-smear negative on expectorated sputum and at least two of four 
TB-related symptoms (cough, fever, weight loss, night sweats) for at least two weeks. Participants were determined 
to have smear-negative disease if 2 expectorated sputa samples, one of which was performed by our research lab, 
were confirmed AFB-smear negative. The time between eligibility and study entry was less than 7 days for all par-
ticipants. Since many participants were unaware of their HIV status at clinical presentation, we offered HIV test-
ing but did not include HIV-infected as either an inclusion or exclusion criterion. We excluded patients who had 
a Karnofsky Performance score < 50 in order to target a relatively well, ambulant population where the majority of 
smear-negative disease is seen, had taken anti-TB medications within the prior three months, or had respiratory 
distress, chronic obstructive pulmonary disease, or cardiac failure. The Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal approved the study, the research methods were carried out in accordance with 
the approved guidelines, and all participants provided written informed consent.
Study procedures. Upon enrollment, we obtained a detailed social and medical history, assessed Karnofsky 
Performance score. Although patients did not require hospitalization, we admitted participants for overnight 
observation in order to obtain one early-morning sputum sample by induction with an ultrasonic nebulizer using 
5% hypertonic saline and obtained a urine sample. Respiratory samples were tested by smear microscopy for AFB 
and cultured for Mycobacterium tuberculosis. Urine samples were obtained at the time of enrollment in a sterile 
container for LAM testing. Participants had chest radiography and additional laboratory testing, including hemo-
globin, serum albumin, and CRP. Participants were offered tuberculin skin testing with purified protein derivative 
and HIV screening, and CD4 count testing if HIV-infected. Since participants were presumed to have had active 
pulmonary TB, all participants were started on empiric therapy after collection of respiratory, blood and urine 
specimens. Participants were referred for initiation of antiretroviral therapy if HIV-infected, in accordance with 
South African guidelines26.
Tuberculosis Testing. Certified technologists performed sputum smear microscopy for AFB and myco-
bacterial culture from respiratory samples in a reference laboratory at the University of KwaZulu-Natal. Sputum 
samples were decontaminated with N-acetyl L Cysteine and NaOH to a final concentration of 1.25% before being 
centrifuged at 3,000 rpm for 20 minutes and resuspended in one milliliter of 7H9 broth. Smear microscopy was 
performed using both Ziehl-Neelson and Auramine stains, and considered positive if either stain revealed AFB. 
Mycobacterial culture was performed by inoculating Middlebrook 7H11 solid agar medium, and inoculating 0.5 
milliliter in liquid mycobacterial growth indicator tubes (MGIT™ ) in an automated Bactec™ 960 instrument 
(BD; Franklin Lakes, USA). Culture plates were read at 3 and 6 weeks, and M. tuberculosis was identified from 
solid or liquid cultures using niacin and nitrate testing. The study was conducted and specimens were collected 
before the Xpert MTB/RIF assay became available in South Africa.
Urine LAM assay testing was performed on urine samples stored in a − 20 °C frost-free freezer using the 
Determine™ TB LAM test (Alere Inc., Waltham, USA) in accordance with the manufacturer’s specifications. 
Urine LAM assay kits from Manufacturer Lot Numbers 110512, 120215, and 120222 were maintained at room 
temperature (15–26 °C). We brought urine specimens to room temperature, centrifuged samples at 10,000 rpm 
for five minutes, and used a sterile pipette to transfer 60 microliters of the clear supernatant to the test strip. Two 
readers (PKD and LG) interpreted the test results after 25 minutes and reached consensus if there was disagree-
ment. LAM assays without positive control lines were considered ‘invalid’ and repeated, but we did not observe 
any test strip failures. Positive LAM assays were graded from low band intensity (1+ grade) to high band intensity 
(5+ grade), according to the manufacturer’s original reference card with five positive categories. We included 
the 1+ grade, since the data were collected before the manufacturer modified the reference card. Operators and 
readers were blinded to participant information during urine LAM and TB testing.
Statistical Analysis. We used sputum culture for M. tuberculosis as the gold-standard diagnostic test for 
active pulmonary TB, and followed STARD guidelines for reporting diagnostic accuracy27. We used Fisher’s 
Exact test for categorical variables and t-test for continuous measures to compare characteristics between TB 
culture-negative and –positive participants. We calculated sensitivity, specificity, predictive values (posi-
tive and negative) for sputum AFB and urine LAM assays, alone and in combination, for diagnosing sputum 
culture-confirmed pulmonary TB. We evaluated the performance of urine LAM in participants categorized 
according to clinical manifestations, levels of inflammatory markers, and immunological status. We used area 
under receiver operating characteristic curves (AUROC) to evaluate overall diagnostic accuracy of sputum smear 
and urine LAM, individually or in combination. Since other rapid, point-of-care tests, such as hemoglobin, CRP, 
and CD4 count, might be used in this setting, we incorporated these in AUROC analyses. We compared AUROC 
estimates using the DeLong test28, reported two-tailed p-values using α = 0.05, and conducted analyses using SAS 
9.4 (Cary, NC, USA).
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Results
Among 90 participants enrolled, mean age was 36.9 years (standard deviation ± 9.3 years) and 44 participants 
(49.1%) were female (Table 1). Fifty-seven participants (63.3%) were diagnosed with culture-confirmed pulmo-
nary TB. Of 85 participants tested, forty-five (52.9%) were tuberculin skin test positive. Among 88 participants 
consented and tested for HIV, 82 (93.2%) were HIV-infected with a median CD4 cell count of 168/mm3 (inter-
quartile range 89–256/mm3). Culture-positive participants had significantly lower Karnofsky Performance scores, 
hemoglobin, and serum albumin, but a significantly higher number of TB-related symptoms and CRP concen-
trations. There were no significant differences in tuberculin skin test positivity, HIV infection, or CD4 count 
between TB culture-negative and -positive participants.
Sputum Smear and Urine LAM Testing. Induced sputum samples from 14 participants (15.6%) were AFB 
smear-positive. The overall sensitivity and specificity of one sputum AFB smear for diagnosing culture-confirmed 
pulmonary TB was 21.1% (95% CI 11.4–33.9%) and 93.9% (95% CI 79.8–99.3%) (Table 2). The urine LAM assay 
Culture-Negative 
Mean ± SD or N (%) 
(N = 33)
Culture-Positive 
Mean ± SD or N (%) 
(N = 57) p-value
Demographics
 Age (years) 36.4 ± 7.6 37.1 ± 10.3 0.71
 Female gender 18 (54.6) 28 (49.1) 0.66
Clinical
 Weight (kilograms) 59.0 ± 7.7 59.4 ± 11.9 0.87
 BMI (kilograms/meter2) 21.7 ± 2.6 21.8 ± 3.9 0.88
 Karnofsky Performance score 0.006
 100 26 (81.3) 27 (48.2)
 90 3 (9.4) 16 (28.6)
 ≤ 80 3 (9.4) 13 (23.2)
 Number of TB-related symptoms* 0.01
 4 symptoms 25 (75.8) 50 (87.7)
 3 symptoms 3 (9.1) 7 (12.3)
 2 symptoms 5 (15.2) 0 (0)
Laboratory Testing
 Hemoglobin (g/dL) 10.8 ± 2.2 9.3 ± 2.1 0.003
 Albumin (g/L) 29.3 ± 6.0 24.7 ± 4.3 0.0005
 C-reactive protein (mg/L) 41.8 ± 49.9 77.3 ± 66.4 0.006
Tuberculosis Testing (n = 85)
 Tuberculin skin test positive 16 (48.5) 29 (55.8) 0.66
HIV Testing (n = 88)
 HIV-infected 29 (87.9) 53 (96.4) 0.19
 CD4 count/mm3 among HIV+ 205 ± 141 195 ± 177 0.78
Table 1.  Baseline cohort characterstics by sputum culture for pulmonary tuberuclosis. BMI = body mass 
index; SD = standard deviation; TB = tuberculosis. *Includes cough, fever, night sweats, weight loss.
Sensitivity Specificity Positive PV Negative PV
N/N % (95% CI) N/N % (95% CI) % (95% CI) % (95% CI)
Sputum AFB Smear 12/57 21.1 (11.4–33.9) 31/33 93.9 (79.8–99.3) 85.7 (57.2–98.2) 40.8 (29.7–52.7)
Urine LAM Assay
 ≥ 1+ grade 24/57 42.1 (29.1–55.9) 28/33 84.9 (68.1–94.9) 82.8 (64.2–94.2) 45.9 (33.1–59.2)
 ≥ 2+ grade 13/57 22.8 (12.7–35.8) 32/33 97.0 (84.2–99.9) 92.9 (66.1–99.8) 42.1 (30.9–54.0)
 ≥ 3+ grade 9/57 15.8 (7.5–27.9) 33/33 100 (89.4–100) 100 (66.4–100) 40.7 (30.0–52.2)
 ≥ 4+ grade 7/57 12.3 (5.1–23.7) 33/33 100 (89.4–100) 100 (59.0–100) 39.8 (29.2–51.1)
 5+ grade 4/57 7.0 (2.0–17.0) 33/33 100 (89.4–100) 100 (39.8–100) 38.4 (28.1–49.5)
Sputum AFB or Urine LAM 
≥ 1+ grade 30/57 52.6 (39.0–66.0) 26/33 78.8 (61.1–91.0) 81.1 (64.8–92.0) 49.1 (35.1–63.2)
Sputum AFB or Urine LAM 
≥ 2+ grade 22/57 38.6 (26.0–52.4) 30/33 90.9 (75.7–98.1) 88.0 (68.8–97.5) 46.2 (33.7–59.0)
Table 2.  Diagnostic accuracy for induced sputum AFB smear and urine LAM assay for diagnosing culture-
confirmed pulmonary TB. AFB = acid-fast bacilli; CI = confidence interval; LAM = lipoarabinomannan; 
PV = predictive value; TB = tuberculosis.
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had a sensitivity and specificity of 42.1% (95% CI 29.1–55.9%) and 84.9% (95% CI 68.1–94.9%). Using a LAM 
grade ≥ 2+ threshold decreased sensitivity to 22.8% (95% CI 12.7–35.8%), and improved specificity to 97.0% 
(95% CI 84.2–99.9%). Overall, using higher band intensities for a positive LAM test threshold reduced diagnostic 
sensitivity, but improved specificity.
There was poor agreement between the urine LAM assay and sputum AFB (κ = 0.08; p = 0.28). Eight partic-
ipants were sputum AFB positive and urine LAM negative, while 23 participants were urine LAM positive and 
sputum AFB negative. When using a combined diagnostic strategy of a positive sputum AFB smear or a positive 
urine LAM test, diagnostic sensitivity increased to 52.6% (95% CI 39.0–66.0%), but specificity decreased to 78.8% 
(95% CI 61.1–91.0%). When using a higher threshold for a positive LAM (grade ≥ 2+ ), sensitivity decreased to 
38.6% (95% CI 26.0–52.4%), while specificity was 90.9% (95% CI 75.7–98.1%).
Urine LAM Assay by Clinical, Inflammatory, and Immunologic Characteristics. The diagnostic 
sensitivity of the urine LAM assay was significantly different when applied to subgroups with particular clinical 
and/or laboratory characteristics (Table 3). The urine LAM assay had higher diagnostic sensitivity among partic-
ipants with a lower Karnofsky Performance score, lower serum hemoglobin, and higher CRP, while there were no 
significant differences by number of TB-related symptoms. Diagnostic sensitivity of urine LAM with 1+ grade 
among participants with a CD4 count less than the median (168/mm3) was 58.6% (95% CI 38.9–76.5%), which 
was significantly better than among those with a CD4 above the median (25.0%; 95% CI 9.8–46.7%). Sensitivity 
of urine LAM was also significantly higher among participants with a serum albumin < 26 g/L (67.9%; 95% CI 
47.7–84.1%), when compared to those with a serum albumin ≥ 26 g/L (17.2%; 95% CI 5.6–35.8%). The results 
were similar using a higher intensity threshold for the urine LAM assay (grade ≥ 2+ ).
There were also significant differences in clinical and laboratory parameters when comparing positive 
low-grade (1+ ) and high-grade (≥ 2+ ) LAM assay results (Table 4). Participants with a high-grade positive urine 
LAM result had significantly lower hemoglobin and serum albumin levels, compared to those with a low-grade 
positive result. Participants with low-grade positive urine LAM were also more likely to be tuberculin skin test 
positive (p = 0.02). There were no significant differences between those with low- and high-grade positive LAM 
tests in sputum AFB smear positivity and mean CD4 count.
Value of Using a Combination of Sputum Smear and Urine LAM Testing. We assessed overall diag-
nostic accuracy of various testing strategies for sputum AFB and urine LAM testing in our cohort (Table 5). 
Induced sputum AFB smear alone had an AUROC of 0.58 (95% CI 0.51–0.64) and the urine LAM assay alone had 
an AUROC of 0.65 (95% CI 0.56–0.73). Combining urine LAM with sputum AFB had an AUROC = 0.68 (95% CI 
0.59–0.77), which was significantly better than induced sputum AFB smear alone (p = 0.006) (Fig. 1). Stratifying 
results by various clinical and laboratory characteristics improved diagnostic outcomes for urine LAM testing, 
Sensitivity
N/N % (95% CI) p-value
Urine LAM grade ≥ 1+ 
 Karnofsky Performance score ≤ 90 18/30 60.0 (40.6–77.3) 0.007
 Karnofsky Performance score 100 6/27 22.2 (8.6–42.3)
 Hemoglobin < 9.8 g/dL 20/34 58.8 (40.7–75.4) 0.003
 Hemoglobin ≥ 9.8 g/dL 4/23 17.4 (4.6–38.8)
 Albumin < 26 g/L 19/28 67.9 (47.7–84.1) 0.0001
 Albumin ≥ 26 g/L 5/29 17.2 (5.6–35.8)
 C-reactive protein < 46 mg/L 5/22 22.7 (7.8–45.4) 0.03
 C-reactive protein ≥ 46 mg/L 18/34 52.9 (35.1–70.2)
 CD4 < 168/mm3 17/29 58.6 (38.9–76.5) 0.03
 CD4 ≥ 168/mm3 6/24 25.0 (9.8–46.7)
Urine LAM grade ≥ 2+ 
 Karnofsky Performance score ≤ 90 12/30 40.0 (22.7–59.4) 0.001
 Karnofsky Performance score 100 1/27 3.7 (0.1–19.0)
 Hemoglobin < 9.8 g/dL 13/34 38.2 (22.2–56.4) 0.0007
 Hemoglobin ≥ 9.8 g/dL 0/23 0
 Albumin < 26 g/L 13/28 46.4 (27.5–66.1) 0.0001
 Albumin ≥ 26 g/L 0/29 0
 C-reactive protein < 46 mg/L 1/22 4.6 (0.1–22.8) 0.02
 C-reactive protein ≥ 46 mg/L 11/34 32.4 (17.4–50.5)
 CD4 < 168/mm3 10/29 34.5 (17.9–54.3) 0.11
 CD4 ≥ 168/mm3 3/24 12.5 (2.7–32.4)
Table 3.  Diagnostic accuracy of urine LAM for diagnosing culture-confirmed pulmonary TB by clinical 
and laboratory results*. CI = confidence interval; LAM = lipoarabinomannan; TB = tuberculosis. *The cut-
offs for each parameter was based on the median value.
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but not for sputum smear testing. The diagnostic value of urine LAM in patients categorized by severity of clinical 
illness, levels of inflammatory markers and degree of immune suppression is also demonstrated by AUROC anal-
ysis (Table 5). The highest AUROC values were for performing urine LAM alone for participants with albumin 
≤ 25 g/L (AUROC = 0.79; 95% CI 0.66–0.92), and both urine LAM and smear AFB for those with a CD4 < 200/mm3 
(AUROC = 0.79; 95% CI 0.69–0.90) (Fig. 2). The combination of urine LAM and sputum AFB was significantly 
better than sputum AFB testing alone across all categories of patients with functional impairment, elevated 
inflammation, and greater immunosuppression.
Discussion
In this study of adults presenting with expectorated smear-negative sputum and symptomatic TB disease, 
the urine LAM assay was beneficial in conjunction with induced sputum smear microscopy for diagnosing 
culture-confirmed pulmonary TB. Overall, a darker band intensity of the urine LAM assay had improved speci-
ficity, or lower false positive rate, but with reduced diagnostic sensitivity. Rapid urine LAM testing was more sen-
sitive at diagnosing TB in patients with more advanced disease, as suggested by presence of severe anemia, lower 
albumin levels, higher acute phase reactants, and a poorer functional state. Conducting the urine LAM assay in 
combination with sputum AFB smear improved diagnostic accuracy, and was most valuable among patients with 
functional impairment (low Karnofsky Performance score), hypoalbuminemia, or a low CD4 count (< 200/mm3).
The diagnostic accuracy of the urine LAM assay has been reported in hospital-based settings, but not from 
an ambulatory population with expectorated smear-negative pulmonary TB. Studies of HIV-infected patients 
presenting to a clinic or hospital with TB-related symptoms have reported a diagnostic sensitivity of urine LAM 
between 62–69%16,19–24, which was higher than our study. This difference may be due to these studies including 
participants with smear-positive by expectorated sputum, which might be a marker for a high bacillary load, 
as well as sicker patients. Since our data showed better overall diagnostic accuracy for combined urine LAM 
testing among sicker patients, the LAM test might have greater value in diagnosing TB in patients that require 
hospitalization for advanced TB. Other studies have also shown the urine LAM assay to have improved sensitivity 
among immunosuppressed adults16,23,24, and among patients with elevated inflammation29. While our study was 
representative of patients presenting with TB-related symptoms regardless of HIV status, urine LAM has limited 
diagnostic value among HIV-negative people30. Our study builds upon previous studies by demonstrating that 
urine LAM adds to the overall diagnostic accuracy among adults who present to the hospital with TB-related 
symptoms, but have an initial negative expectorated sputum AFB smear microscopy.
The urine LAM assay is an imperfect pathogen biomarker for an active TB infection, but may provide addi-
tional diagnostic value in certain clinical settings. The increased specificity with darker LAM band intensity 
suggests a greater bacillary load of TB, which is consistent with our previous finding that LAM decreases with 
anti-TB therapy17. The finding that people with a higher LAM grade had significantly lower hemoglobin and 
albumin levels, but higher CRP levels, further suggests that a darker LAM band is associated with a greater overall 
burden of TB disease. Since the LAM band intensity ≥ 3+ had a diagnostic specificity of 100%, or no false posi-
tive results, the presence of a strong LAM band intensity provides good diagnostic value to clinicians. However, 
Urine LAM ≥1+ grade 
Mean ± SD or N (%) (N = 15)
Urine LAM ≥2+ grade 
Mean ± SD or N (%) (N = 14) p-value
Clinical
 Weight (kilograms) 58.0 ± 6.1 59.2 ± 15.6 0.80
 BMI (kilograms/meter2) 20.9 ± 2.8 22.1 ± 4.5 0.43
 Karnofsky Performance score 0.12
 100 8 (53.3) 2 (15.4)
 90 3 (20.0) 3 (23.1)
 ≤ 80 4 (26.7) 8 (61.5)
 Number of TB-related symptoms* 1.0
 4 symptoms 14 (93.3) 13 (92.9)
 3 symptoms 1 (6.7) 1 (7.1)
 2 symptoms 0 (0) 0 (0)
Laboratory Testing
 Hemoglobin (g/dL) 9.1 ± 1.9 7.4 ± 1.4 0.007
 Albumin (g/L) 25.1 ± 3.3 20.5 ± 2.3 0.0002
 C-reactive protein (mg/L) 67.5 ± 41.7 119.1 ± 88.0 0.07
Tuberculosis Testing
 Tuberculin skin test positive (n = 85) 10 (66.7) 2 (16.7) 0.02
 Sputum AFB smear positive 3 (20.0) 3 (21.4) 1.0
HIV Testing (n= 88)
 CD4 cells/mm3 among HIV+ 152 ± 107 143 ± 154 0.85
Table 4.  Clinical and laboratory test results by positive urine LAM grade. AFB = acid-fast bacilli; 
BMI = body mass index; SD = standard deviation; TB = tuberculosis. *Includes cough, fever, night sweats, 
weight loss.
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with a peak sensitivity of only 68% among the most severely ill patients, the rapid urine LAM test should not be 
used to rule out or exclude active TB disease. Further refinement of the existing LAM assay, as well as algorithms 
incorporating the urine LAM test with other rapid diagnostic TB tests, may be valuable. In addition, the positive 
predictive value of urine LAM testing will depend upon the prevalence of TB disease in the population, or the 
pre-test probability of disease, which will be different for an ambulatory clinical population as well as various 
geographical regions.
Among the entire cohort, the urine LAM assay improved the overall diagnostic accuracy of induced sputum 
AFB testing alone. Since the benefit was most pronounced among patients with functional impairment, more sys-
temic inflammation, and a greater immunodeficiency, hospital-based settings with existing sputum AFB capacity 
should consider adding rapid urine LAM testing. The overall diagnostic accuracy of urine LAM was superior to 
AFB smear of induced sputa, suggesting that implementation of point-of-care urine LAM testing would be valu-
able. However, similar to smear microscopy, clinicians should not rely upon negative urine LAM testing alone to 
exclude active TB disease in HIV-endemic regions.
Since sputum culture is an imperfect gold standard test for pulmonary TB and we did not perform a complete 
evaluation for extrapulmonary disease, the specificity of urine LAM should be interpreted with caution. A more 
comprehensive assessment for active extrapulmonary TB infection may reduce the misclassification of positive 
urine LAM results among people with culture-negative TB disease. However, urine LAM testing identified signif-
icantly more people with active TB, has a lower occupational risk to health workers, and may be easier to imple-
ment than sputum AFB microscopy. In addition, sputum induction is not generally practiced in resource-limited 
TB-endemic regions, including South Africa, due to a lack of equipment and trained respiratory therapists. Since 
a challenge in the TB-endemic has been identifying TB-infected people, perhaps a small percentage of calculated 
overtreatment may be acceptable under better performing rapid TB diagnostic strategies.
Our study has several strengths and limitations. Primary strengths of this study were recruiting sequential 
patients with symptoms highly suggestive of active pulmonary TB, but with expectorated sputum that was AFB 
smear negative, comparing diagnostic strategies using several clinical parameters and inflammatory biomarkers, 
and assessing both liquid and solid mycobacterial culture as the gold standard. Limitations included obtaining a 
single respiratory sputum sample and not performing comprehensive measures for extrapulmonary TB, includ-
ing mycobacterial blood cultures, both of which may have missed patients with active TB. Urine LAM testing 
was performed on thawed, not fresh, urine samples, and it is unclear if this could impact urine LAM results. We 
also did not evaluate sputum gram stain or epithelial cell count to determine the adequacy or contamination 
of each sputum specimen. However, we did perform nebulized sputum induction, which has been reported to 
AUROC (95% CI)
p-value vs.  
Sputum AFB smear
TB Testing Strategies (n = 90)
 Sputum AFB smear positive 0.58 (0.51–0.64) —
 Urine LAM assay positive 0.65 (0.56–0.73) 0.189
 Sputum AFB or LAM assay positive 0.68 (0.59–0.77) 0.006
If Karnofsky Performance score ≤ 90 (n = 37)
 Sputum AFB smear positive 0.58 (0.52–0.65) —
 Urine LAM assay positive 0.76 (0.63–0.89) 0.013
 Sputum AFB or LAM assay positive 0.78 (0.66–0.90) 0.002
If Hemoglobin ≤ 10 g/dL (n = 49)
 Sputum AFB smear positive 0.58 (0.47–0.69) —
 Urine LAM assay positive 0.69 (0.55–0.82) 0.227
 Sputum AFB or LAM assay positive 0.71 (0.56–0.85) 0.026
If Albumin ≤ 25 g/L (n = 37)
 Sputum AFB smear positive 0.57 (0.43–0.71) —
 Urine LAM assay positive 0.79 (0.66–0.92) 0.027
 Sputum AFB or LAM assay positive 0.77 (0.61–0.94) < 0.001
If C-reactive protein ≥ 25 mg/L (n = 60)
 Sputum AFB smear positive 0.59 (0.50–0.68) —
 Urine LAM assay positive 0.66 (0.54–0.78) 0.401
 Sputum AFB or LAM assay positive 0.71 (0.58–0.83) 0.028
If CD4 < 200/mm3 (n = 48)
 Sputum AFB smear positive 0.64 (0.56–0.71) --
 Urine LAM assay positive 0.72 (0.60–0.83) 0.265
 Sputum AFB or LAM assay positive 0.79 (0.69–0.90) 0.003
Table 5.  Comparison of area under receiver operating characteristic curves (AUROC) to assess overall 
diagnostic accuracy of testing strategies for diagnosing culture-confirmed pulmonary TB. AFB = acid-
fast bacilli; AUROC = area under receiver operating characteristic curve; CI = confidence interval; 
LAM = lipoarabinomannan; TB = tuberculosis.
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being equivalent to lower respiratory tract sampling by bronchoalveolar lavage31. We evaluated diagnostic tests 
among patients presumed to have TB in a region with a high prevalence of TB and HIV, which limits the study’s 
generalizability.
In conclusion, the urine LAM assay is a relatively inexpensive test (US $2.66/test on 7 January 2015)32 that 
can be readily performed to identify more cases of HIV-associated pulmonary TB33. An overnight hospital stay is 
not required to obtain an early morning induced sputum, and the value of testing might be optimized with both 
early morning sputum and urine LAM testing. Urine LAM testing had most benefit among patients with func-
tional impairment, elevated inflammation, or greater immunosuppression, who likely had a higher TB bacillary 
load, and may be best utilized in conjunction with sputum AFB smear for patients presenting with TB-related 
symptoms in HIV-endemic settings. Additional studies are needed to model these diagnostic parameters into an 
optimal algorithm with various levels of disease prevalence.
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